Introduction
Oral solid dosage forms (OSDs) comprise 66% to 70% of all prescribed and dispensed products worldwide. They include tablets, capsules, powders, and lozenges, each of which is designed to deliver active pharmaceutical ingredients (APIs) in a stable, convenient, and patient-friendly manner.
The market for oral solid dosage forms is also undergoing exponential growth. Valued at USD 645.42 billion in 2023, the OSD manufacturing market is projected to expand to USD 1,128.02 billion by 2032, growing at a CAGR of 6.4% over the forecast period (2025–2032).
However, when it comes to specific dosage forms, tablets remain the most widely prescribed and dispensed oral solid dose (OSD), capturing approximately 53.1% of the global OSD market in 2021, followed by capsules, powders, and lozenges. The widespread popularity of tablets stems from their manufacturing and logistical advantages and their preference over other dosage forms among patients and healthcare providers.
Despite their immense use, ensuring compliance and efficacy of oral solid dosage forms remains integral and requires an understanding of regulatory expectations and scientific principles. Regulatory authorities like the FDA, EMA, and WHO have established stringent guidelines to regulate the design, testing, and manufacture of OSDs, complying with which is essential for market approval and to safeguard product quality, stability, and patient safety.
At the same time, achieving therapeutic efficacy of these drugs requires precise control over formulation variables, bioavailability, and release kinetics so that the drug performs as intended in real-world clinical settings.
In this article, we will cover all factors pertaining to ensuring compliance and efficacy of oral solid dosage forms. We will also outline strategies that can be applied throughout the development lifecycle—from formulation and process design to manufacturing, quality control, and patient-centered optimization to ensure regulatory compliance and optimal therapeutic performance of oral solid dosage forms
So, without further delay, let’s dive right into the article.
What are Oral Solid Dosage Forms?
Oral Solid Dosage Forms (OSDs) are pharmaceutical drug products intended for administration via the oral route, in a solid state. OSDs are formulated into a variety of dosage forms, including tablets, capsules, caplets, etc.
Based on the required release pattern of APIs from these drug products, OSDs can be formulated as immediate release forms and modified release forms (extended release, delayed release, controlled release, and sustained release).
Tablets make up most of the OSDs, accounting for up to 53.1% market share of the oral solid dosage formulation market in 2021. The other solid forms that make up the remainder are capsules, caplets, lozenges, and powders.
According to the World Health Organization (WHO) and US FDA, OSDs are the most preferred dosage forms due to their ability to deliver consistent and controlled quantities of active ingredients with a high degree of precision.
Why OSDs Dominate the Market
OSDs remain the preferred formulation type for both manufacturers and patients because of several advantages. These include:
Convenience
OSDs are non-invasive, portable, and easy to self-administer. In fact, several studies have shown that patients prefer tablets and capsules over injections or other delivery routes due to ease of use and minimal discomfort.
Stability
Oral solid forms offer superior physicochemical and microbiological stability compared to liquids or injectables. According to the European Medicines Agency (EMA), solid dosage forms are less susceptible to degradation by heat, light, and moisture, resulting in their extended shelf life and reduced need for cold chain logistics.
Cost-effectiveness
The manufacturing, packaging, and transportation costs of OSDs are significantly lower than those of parenteral or liquid formulations.
(All Rights Reserved)